Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EfaRiLipidomics: Switch from Atripla to Eviplera and plasma lipid profile
2015-002319-13Phase 4Completed
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of emtricitabine + rilpivirine + tenofovir disoproxil fumarate and tenofovir disoproxil fumarate in human immunodeficiency virus infection (HIV) and Human immunodeficiency virus infection type 1 (2 arms), sponsored by Vall d'Hebron Research Institute. Started Jul 2015; status: completed.
02
Drugs
emtricitabine + rilpivirine + tenofovir disoproxil fumaratetenofovir disoproxil fumarate
03
Conditions
human immunodeficiency virus infection (HIV)Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2015-002319-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002319-13.